CHA ÀÇ°úÇдëÇб³ Â÷º´¿ø professor

±³¼ö´Ô»çÁø
  • ±èµ¿Çö
  • ÇǺΰúÀå
  • ¼Ò ¼Ó: ºÐ´çÂ÷º´¿ø
  • Àü¹®ºÐ¾ß : °Ç¼±/ÇǺξÏ/»ö¼Ò¼ºÁúȯ/Å»¸ð/µÎÇÇÁúȯ
  • Á÷ À§: ±³¼ö(ÇǺΰúÀå)
  • ¸Þ ÀÏ: ºñ°ø°³
  • Àü È­: 1577-4488
  • ÆÑ ½º:
  • ÁÖ ¼Ò: °æ±âµµ ¼º³²½Ã ºÐ´ç±¸ ¾ßž·Î 59
  • ȨÆäÀÌÁö:
  • ·Î±×ÀÎ

ÅǸ޴º

ÁÖ¿ä¹ßÇ¥³í¹®

ÁÖ¿ä¹ßÇ¥³í¹®
¹øÈ£ ±¸ºÐ Á¦¸ñ
165 (±¹³»)KCI Ç÷Áß ÃÑ ¸é¿ª±Û·ÎºÒ¸° E°¡ Áõ°¡µÈ °Ç¼± ȯÀÚÀÇ ÀÓ»óÀû Ư¡: ÈÄÇâÀû ´ÜÀϱâ°ü ¿¬±¸
164 (±¹¿Ü)SCI Clinical outcomes in adult patients with plaque psoriasis treated with ustekinumab under real-world practice in Korea: A prospective, observational, multi-center, postmarketing surveillance study
163 (±¹³»)KCI ¾È°Ë ¼ºÇü¼ú ÈÄ ¹ß»ýÇÑ ÈäÅÍ À¯À°Á¾Áõ 1¿¹
162 (±¹³»)SCIE Clindamycin mono-therapy of Hidradenitis suppurativa patients : A single-center retrospective study
161 (±¹³»)SCIE Hyaluronan Oligosaccharides Improve Rosacea-like Phenotype through Anti-inflammatory and Epidermal Barrier-improving Effects
160 (±¹³»)KCIÈĺ¸ °Ç¼± ȯÀÚ¿¡¼­ adalimumab Ä¡·á Áß ¹ß»ýÇÑ BÇü °£¿°ÀÇ ÀçÈ°¼ºÈ­
159 (±¹³»)KCI ¹é¹ÝÁõÀÇ ¹ßº´±âÀü
158 (±¹¿Ü)SCIE Development of Evidence-based Consensus on Critical Issues in the Management of Patients with Vitiligo: A Modified Delphi Study
157 (±¹³»)KCIÈĺ¸ COVID-19¿Í °Ç¼±
156 (±¹³»)SCIE Facial redness in atopic dermatitis patients treated with dupilumab: a case series
ÀÌÀüÆäÀÌÁö À̵¿ 1 2 3 4 5 6 7 8 9 10 ´ÙÀ½ÆäÀÌÁö À̵¿
Copyright ¨Ï chamc, All rights reserved.

ºü¸£°í Æí¸®ÇÑ ÀÎÅÍ³Ý Áø·á¿¹¾à

  • °­³²Â÷º´¿ø
  • ºÐ´çÂ÷º´¿ø
  • ºÐ´çÂ÷¿©¼ºº´¿ø
  • ±¸¹ÌÂ÷º´¿ø
  • ¿©¼ºÀÇÇבּ¸¼Ò
  • Â÷¿ò

ÀüÈ­¹®ÀÇ

  • °­³²Â÷º´¿ø 02.3468.3000
  • ºÐ´çÂ÷º´¿ø 031.780.5000
  • Â÷¿ò 02.3015.5300
  • ±¸¹ÌÂ÷º´¿ø 054.450.9700
  • ´ë±¸¿©¼ºÂ÷º´¿ø 02.222.4200
  • °­³²°ÇÁø¼¾ÅÍ 02.2191.3900
  • ºÐ´çÁ¾ÇÕ°Ç°­ÁõÁø¼¾ÅÍ 031.780.5940
  • ½ºÆ÷·º½º °ÇÁø¼¾ÅÍ 02.3473.2111
  • ±¸¹ÌÂ÷º´¿ø°ÇÁø¼¾ÅÍ 054.450.9800
  • ȨÆäÀÌÁö°ü¸®ÀÚ 031.780.1729